HDAC9 and acute myeloid leukemia: In summary, the findings of the present study demonstrate a highly synergistic interaction between the HDAC inhibitor chidamide and the menin-MLL interaction inhibitor MI-3 both in vitro and in vivo in AML cells with MLL-rearrangement.